Get the Stockscreener App
193.76
2.26%
4.29
After Hours:
193.76
Biogen Inc stock is traded at $193.76, with a volume of 892.90K.
It is up +2.26% in the last 24 hours and up +1.94% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$189.47
Open:
$190.53
24h Volume:
892.90K
Relative Volume:
0.79
Market Cap:
$28.61B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
20.79
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+0.42%
1M Performance:
+1.94%
6M Performance:
+10.53%
1Y Performance:
+53.41%
1-Day Range:
$190.00
$194.75
1-Week Range:
$185.85
$194.75
52-Week Range:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
193.76 | 27.97B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen stock (US09062X1037): Q1 2026 earnings beat rekindles investor interest - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Parkinson’s drug from Biogen, Denali comes up short - BioPharma Dive
William Blair Maintains Biogen(BIIB.US) With Buy Rating - Moomoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Biogen Inc. (BIIB) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish - Investing.com
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish - MarketBeat
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop - BioSpace
Biogen, Denali to drop Parkinson’s therapy (BIIB:NASDAQ) - Seeking Alpha
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints - TradingView
Biogen, Denali scrap Parkinson’s candidate after Phase IIb miss - The Pharma Letter
Biogen, Denali axe LRRK2 inhibitor in idiopathic Parkinson’s after mid-stage miss - FirstWord Pharma
Biogen stock (US09062X1037): Parkinson’s drug setback hits pipeline - AD HOC NEWS
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data - Stock Titan
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results - GuruFocus
Biogen and Denali Therapeutics Halt BIIB122 Development After Tr - GuruFocus
Biogen and Denali halt BIIB122 development after Phase 2b Parkinson's study fails to meet endpoints - Pluang
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study - WNWN-FM
Biogen, Denali discontinue Parkinson’s drug after trial fails By Investing.com - Investing.com Australia
[8-K] Denali Therapeutics Inc. Reports Material Event - Stock Titan
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen
Biogen and Denali Therapeutics Provide Update on Phase 2b - GlobeNewswire
Biogen Patent Suit Targets Somerset’s Copy of Spinraza Therapy - Bloomberg Law News
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock (US09062X1037): FDA decision keeps investors focused - AD HOC NEWS
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB) - GlobeNewswire
Are Wall Street Analysts Bullish on Biogen Stock? - Yahoo Finance
How Biogen’s Diranersen Alzheimer’s Bet Will Impact Biogen (BIIB) Investors - simplywall.st
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st
Biogen stock (US09062X1037): Alzheimer data and Q1 earnings keep focus on biotech transition - AD HOC NEWS
Biogen Earnings Call Signals Confident, Investment-Heavy Transition - TipRanks
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud - Business Wire
Biogen Inc (BIIB) Stock Price, Trades & News - GuruFocus
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Biogen stock (US09062X1037): Alzheimer’s focus after Leqembi setback and pipeline updates - AD HOC NEWS
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Investigation launched into Biogen after Alzheimer's drug trial misses key goal, stock drops sharply. - Pluang
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
2.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):